Cure those hot flashes and more with our helpful menopause resources
NEW POSITION PAPER: Here Is the NAMS 2010 Position Paper on Estrogen and progestogen use in postmenopausal women. Click here to read the report in its entireity.
His and Her Health | Promote Your Page Too
| Risk of Fracture of Subtrochanteric or Diaphyseal Femur Linked With Bisphosphonate Called 'Very Low' |
|
|
|
| Monday, 29 March 2010 | |
|
A study reported in the March 25, 2010 New England Journal of Medicine "concludes that the risk of fracture of the subtrochanteric or diaphyseal femur associated with bisphosphonate use is very low, even in women with Osteoporosis who received Bisphosphonates for up to 10 years. Given the limitation of a small number of events and wide confidence intervals, these studies did not show a significant increase in the risk of subtrochanteric or diaphyseal fracture with 3 to 4 years of use of alendronate or zoledronic acid or up to 10 years of alendronate use, the New England Journal of Medicine (NEJM) study said. An editorial with the report noted that "the results provide assurance that subtrochanteric fractures are extremely rare, as compared with femoral-neck and intertrochanteric fractures. The findings also suggest that many more common and equally devastating hip fractures are prevented by bisphosphonates than are potentially caused by the drugs." This information should be reassuring to all individuals with osteoporosis that their medications are safe and effective for the purpose for which they were intended. I found this an important study and have linked it to the article in NEJM. You can see it in full by clicking here. You can also check an editorial on the topic on NEJM by clicking here. |
|
| Last Updated ( Monday, 29 March 2010 ) |